Peptide CRO/CMO News | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.

All posts in Peptide CRO/CMO News

Creative Peptides to Reorganize Its Peptide Synthesis Services for Science Community

Creative Peptides announced to reorganize its peptide synthesis services.

Shirley, New York (November 21, 2018) One of the world’s leading peptide suppliers Creative Peptides announced to reorganize its peptide synthesis services on November 21, 2018. Now this business is distinctively divided into three categories, namely, custom peptide design, custom peptide synthesis and GMP grade peptide synthesis.

As the pharmaceutical industry develops rapidly, there are an increasing demand for peptide synthesis. And with the discovery of biologically active peptides, the objectives of synthesis also change dramatically.

“Peptide design is the very first step of any meaningful studies about proteins and peptides. During this step, several factors such as the length of sequence, amino acid residues and the sequence of peptides need to be carefully considered as they are vital to correct assembly and purification. So we generally adopt some strategies to design peptide better,” explains Dr. Robert Martinez, head of Creative Peptides’ synthesis businesses, in a statement.

When everything gets prepared, a peptide synthesis project is initiated. “There are two types of peptide synthesis: solid phase synthesis and liquid phase synthesis. And in fact, the solid phase synthesis method has become a kind of common technique in the synthesis of peptides and proteins,” further expounds Dr. Robert. “In addition, all products synthesized by Creative Peptides meet GMP standards as all our production sites were designed in strict accordance to US-FDA guidelines for GMP Manufacturing.”

Peptide synthesis has proven to be useful in the following applications:

Biological effect measurements;

Peptide array and microarray printing;

Enzymology and biological activity screening;

Vaccine development;

Receptor characterization and receptor-ligand interactions;

Mass spec standard development and studies;

Protein function-structure analysis;

Peptide for drug discovery;

Therapeutic peptide drugs;

Biophysical studies;

For additional information and for peptide synthesis pricing, please contact contact@creative-peptides.com or visit https://www.creative-peptides.com/services/peptide-synthesis-services.html.

About Creative Peptides

With over a dozen of years’ experience in peptide manufacturing and synthesis, Creative Peptides has now gained a fame in custom peptide synthesis, GMP manufacturing, API peptides, cosmetic peptides, catalog peptides, etc. With the advantage of excellent scientific teams consisting of experts in multiple fields like peptide technology, antibodies as well as synthetic chemistry, Creative Peptides now focus more on satisfying different needs of customers by providing a wide range of services, including peptide drug discovery, bioconjugations, stapled peptide synthesis, cell penetrating peptides, etc.

Media Contact
Company Name: Creative Peptides
Contact Person: Caroline Miller
Email: Send Email
Phone: 1-631-619-7922
Address:45-16 Ramsey Road
City: Shirley
State: NY
Country: United States
Website: www.creative-peptides.com/

Lonza to Establish Strategic Biomanufacturing Base in China Using GE Healthcare Solution

Basel (CH) and Guangzhou (CN), 10 December 2018 – Lonza today announced an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou (CN). As the facility is part of a larger biomanufacturing initiative between GE Healthcare and Guangzhou Development District (GDD), the agreement will be finalized when contracts have been signed with the GDD. Later today, Lonza will sign a memorandum of understanding with the GDD to take the project forward. The new facility will give Lonza Pharma & Biotech a strategic base in China to respond to growing demand for high-quality CDMO services in the country.

By working with GE Healthcare to develop the new facility, based on the KUBio platform, an off-the-shelf biologics factory, Lonza intends to offer its suite of antibody development services and manufacture GMP-certified batches by 2020. The two companies will work closely on the design of the 17,000m2 site, which will include 6,500m2 of lab space and one KUBio facility.

The labs will house Lonza’s proprietary platforms for cell-line construction, including the GS Gene Expression System®, as well as process development, cell banking and pilot labs. The KUBio unit will enable small-scale GMP manufacturing equipped with GE Healthcare’s single-use biomanufacturing technologies, including 1,000 and 2,000L bioreactors, combined with Lonza’s automation platforms for clinical and early-commercial supply.

“This partnership is the ideal way for Lonza to bring our expertise and technology to China,” said Marc Funk, COO Lonza Pharma & Biotech. “The combination of a strong and experienced technology provider with a long history in China, together with a dynamic regional authority, means that we can rapidly offer services to customers and ultimately get innovative therapies to patients more quickly.”

GE Healthcare is working with the GDD to support large-scale manufacturing of biopharmaceuticals in China.

“With Lonza coming on site, a hub of biotech is truly taking shape,” said Emmanuel Ligner, President and CEO, GE Healthcare Life Sciences. “This agreement is yet another step in realizing our vision of enabling and supporting manufacturers of all sizes to quickly deploy capacity and meet increasing customer demand for biologics.”

The facility in China will extend Lonza Pharma & Biotech’s global biologics network that provides development and manufacturing services from gene through IND and BLA to mature commercial supply. In addition to the new Chinese site, the network comprises small-, mid- and large-scale assets in Switzerland, the United States, the UK, Spain and Singapore.

Lonza plans to hire and train more than 160 staff, and the new site will benefit from the company’s global standards of technological and operational excellence. With more than 20 successful FDA approvals for biologics, combined with international regulatory expertise, Lonza will now be able to offer the same high standards in China as it does elsewhere.

China has been historically underserved by biologics, but demand for antibody therapies is expected to grow significantly over the coming years. A strong scientific base and commercial instruments put into place by the Chinese authorities are encouraging their domestic companies developing innovative therapies for the global market, as well as multinationals with manufacturing requirements in the country. In particular, national rollout of the Marketing Authorization Holder scheme by 2019 paves the way for dedicated CDMO services in China.

Almac Invests in Next-Generation Sequencing Capabilities

On Oct. 11, 2018, Almac Diagnostic Services, which specializes in biomarker driven clinical trials, has added a Illumina NovaSeq 6000 sequencer to ...

Lonza to buy Shire’s Cali mammalian manufacturing plant

Lonza cited increasing demand for clinical-stage manufacturing and said “the acquisition of the site will provide additional cGMP capacity and will ...

Evonik buys into low-cost peptides

Numaferm claims it can make peptides at 1/1,000th of the price of standard chemical process costs (about $1.2 million per kg). Numaferm's technology ...

Catalent bolsters biopharma business with Cook Pharmica buy

Swiss pharmaceutical supplier Lonza Group AG (LONN.S) last year said it would buy Capsugel, a U.S. maker of capsules and other drug delivery ...

Biosimilars Market worth 10.90 Billion USD by 2021
The global biosimilars market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3%. The market is broadly classified into product, manufacturing type, application, and region.

The report "Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO) & Application (Oncology, Blood Disorders) - Global Forecast to 2021", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the biosimilars market along with the estimates and forecasts of the revenue and market share analysis.

The global biosimilars market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3% during the forecast period. The major factors driving the growth of this market are the increasing demand for biosimilar drugs due to their cost-effectiveness, growing pressure to curtail healthcare expenditure, rising geriatric population, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars.

Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=40

This report segments the market on the basis of product, manufacturing type, application, and region. On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. In 2016, the recombinant non-glycosylated proteins segment is expected to account for the largest share of the market. New product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are the factors driving the growth of this segment.

Based on manufacturing type, the biosimilars market is segmented into in-house manufacturing and contract manufacturing organizations. In 2016, the contract manufacturing segment is expected to account for the largest share of the market.

Based on application, the biosimilars market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The oncology segment is expected to grow at the highest CAGR during the forecast period. The rising incidence of cancer, high cost of biologics, pressure to reduce healthcare expenditure, and low cost of biosimilars are factors contributing to the growth of this segment.

Based on region, the global biosimilars market is segmented into North America, Europe, Asia, and RoW. Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to factors such as the low per capita consumption, rapid growth in economies, rise in technological innovation, trade links, and the rise in medical tourism.

The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy’s Laboratories (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).

Agilent Technologies Extends Biopharma Portfolio with Advanced Mass Spec System

SANTA CLARA, Calif.--(BUSINESS WIRE)--

Agilent Technologies Inc. (NYSE:A) introduces the latest addition to its portfolio of solutions for biopharmaceutical labs: the Agilent 6545XT AdvanceBio LC/Q-TOF MS System.

Optimized to address analytical workflows commonly used in biopharma, the new LC/Q-TOF MS system combines high-performance liquid chromatography with robust quadrupole time-of-flight mass spectrometry and data-analysis tools. A research-grade system, the 6545XT is designed to deliver superior results to scientists seeking to characterize biomolecules that could be the basis for new therapeutics.

“Agilent is committed to providing complete workflow solutions to the biopharma industry that address critical areas for biotherapeutic development,” said Monty Benefiel, Agilent vice president and general manager of the company's Mass Spectrometry Division. “Agilent solutions built around the 6545XT enable scientists to characterize biomolecule structure and function more efficiently than ever, resulting in reduced time to market and improved drug efficacy.”

The 6545XT has also been optimized for use in profiling intact proteins, mapping peptides and identifying post-translational modifications.

Additionally, Agilent’s solutions for these types of workflows are further enhanced by the Agilent AdvanceBio LC column portfolio including the introduction today of a new column: the AdvanceBio Peptide Plus column. This column is designed for LC/MS peptide separations utilizing our unique superficially porous particle technology.

These new products complement and optimize Agilent’s existing biopharma portfolio, which includes products for sample preparation, separation, detection and analysis.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005935/en/

UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as …

PR Newswire

SAN DIEGO, March 7, 2017

SAN DIEGO, March 7, 2017 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes, today announced that the company's CEO and Co-founder, Jack W. Reich, Ph.D., has been selected as a keynote speaker for the prestigious UNIAPAC Foundation Think Tank meeting on March 17, 2017, in Paris.

The aim of this annual meeting is to lead a candid and open debate among academics, business leaders and distinguished guests, to provide insights on the main socioeconomic challenges of the 21st century. The meeting brings together 24 high-level attendees and includes a full set of presentations and dialogue sessions.

A pioneer in the field, Dr. Reich will be speaking on the social, economic and healthcare delivery implications of gene therapy.

"I'm honored to engage on the topic of gene therapy with bright minds who are dedicated to finding solutions to some of the world's greatest challenges," says Dr. Reich. "Our mission at Renova Therapeutics – to create transformational therapies that treat the world's most prevalent diseases – fits closely with the goals of UNIAPAC and its foundation. We're focused on treating chronic diseases that have a debilitating impact on hundreds of millions of people worldwide – and doing so by potentially reversing the disease process, rather than treating symptoms. Diminishing these major threats to global health would have tremendous socioeconomic impact."

Founded in 1931, UNIAPAC is an ecumenical union that groups together Christian Business Leader associations in 40 countries in Europe, Latin America, Africa and Asia. UNIAPAC represents more than 30,000 active business executives working in various leading sectors of the world economy. The organization's goal is to promote a vision and deployment of Corporate Social Responsibility focused on the human person, with a view of bringing about change in business attitudes toward more responsible and sustainable economic, social and human progress.

The UNIAPAC Foundation was created in 2010 with the intent to actively assist UNIAPAC National Associations in their local initiatives and support their activities at an international level. The foundation is a key facilitator in UNIAPAC's continuous dialogue with all men and women of goodwill who are interested in ensuring the rightful place of the human person in the economy.

Dr. Reich will lead one of four panels at the foundation's think tank meeting.

About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com .

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uniapac-foundation-think-tank-in-paris-selects-renova-therapeutics-ceo-and-co-founder-as-keynote-speaker-for-annual-meeting-300418810.html

SOURCE Renova Therapeutics

PR Newswire
www.prnewswire.com

Last updated on: 07/03/2017

Allegro Ophthalmics Names Melvin Sarayba, MD, Vice President of Clinical Affairs

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--

Allegro Ophthalmics, LLC, a biotechnology company focused on the development of novel therapies to treat vitreoretinal diseases, today announced that Melvin Sarayba, MD, has joined the company as vice president of clinical affairs. In his new role, Dr. Sarayba is responsible for Allegro's US and international clinical program for Luminate®, which met its primary and secondary endpoints in the DEL MAR Phase 2b clinical trial for diabetic macular edema (DME), the company announced in October, 2016.

An ophthalmic surgeon with an extensive clinical research background and two decades of product development and commercialization experience, Dr. Sarayba has worked for multiple successful ophthalmic companies, including IntraLase, AMO, WaveTec, LenSx Lasers, Alcon Laboratories and ClarVista Medical. At LenSx, he served as vice president of clinical affairs leading the company’s efforts on ophthalmic medical device product development, product improvement, and new applications. Dr. Sarayba also has designed and led clinical trials at various stages of the life cycle. As the head of global medical affairs for the cataract franchise at Alcon, he was responsible for key clinical initiatives for the company’s entire cataract portfolio. Dr. Sarayba completed his fellowship training at the University of California, Irvine. He is a prolific innovator with 10 patents and has authored or co-authored numerous peer-reviewed publications.

"Melvin's history of successfully running pivotal clinical trials for innovative startup companies like IntraLase and LenSx and for respected industry leaders like Alcon and AMO make him a valuable addition to the Allegro team,” says Hampar Karageozian, MSc, MBA, co-founder and chief executive officer, Allegro Ophthalmics. “I am confident that Dr. Sarayba will be an enormous asset to Allegro and will continue to propel Luminate, which has thus far shown very promising efficacy and safety results in Phase 2 clinical trials across multiple indications, through trials and on to commercialization."

About Luminate

Luminate, a first-in-class integrin peptide therapy, treats vitreoretinal diseases by targeting integrin receptors involved in cell signaling and regulation and in the construction of new and aberrant blood vessels. By utilizing two mechanisms of action (vitreolysis and anti-angiogenesis), Luminate has been shown in clinical studies to date to effectively regress and inhibit new blood vessel formation, as well as reduce vascular leakage to maintain and restore vision. Currently in Phase 2 clinical trials for multiple indications, including diabetic macular edema (DME) and non-proliferative diabetic retinopathy (NPDR), Luminate is an investigational drug not approved by the FDA for commercial sale in the U.S. Allegro maintains commercial rights to Luminate in all territories outside of Japan, Korea and China.

About Allegro Ophthalmics, LLC

With more than 100 years of combined experience in ophthalmic drug discovery, development and manufacturing, Allegro Ophthalmics, LLC, is working to establish integrin peptide therapy as the next-generation pharmaceutical category for the treatment of vitreoretinal diseases. Allegro’s lead investigational drug, Luminate, is currently in Phase 2 studies and has the potential to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with diabetic macular edema, diabetic retinopathy, wet age-related macular degeneration, and vitreomacular traction. By quickly, safely and cost-effectively bringing to market new and improved treatment options for leading causes of blindness, Allegro is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision. For more information, visit www.allegroeye.com.

Luminate® is a registered trademark of Allegro Ophthalmics, LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005553/en/

 
 
 
 

s2Member®
loading...